Ken leads the clinical pharmacology, bioanalytical, and toxicology functions. He has more than 20 years of nonclinical and clinical drug development experience, particularly in the areas of DMPK, clinical pharmacology, and pharmacometrics. Prior to joining Anaptys, Ken held various positions at Pfizer, Allergan and Ionis Pharmaceuticals and supported a wide range of drug modalities including small molecules, monoclonal antibodies, antibody-drug conjugates, and oligonucleotides. He has worked in teams that contributed to the approvals of products such as Besponza™, Spinraza®, and Durysta™. Ken received his Ph.D. in Pharmaceutical Sciences at the University of the Pacific and his B.S. in Biological Sciences at the University of California, Irvine.